PROTACs

  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • Ddi1 is a ubiquitin-dependent protease

    Ddi1 is a ubiquitin-dependent protease

    Read
  • Protein degraders show promising results in drug development pipelines. See what progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See what progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • Characterizing interactions involving PROTACs or other TACs?

    NanoTemper tools can help

    Find out how
  • Are you building an effective protein degrader?

    Are you building an effective protein degrader?

    Read
  • Are you building an effective protein degrader? 4 questions to ask yourself to find out

    Are you building an effective protein degrader? 4 questions to ask yourself to find out

    Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...

    Read
  • Have a question?

    Contact Specialist
  • ×

    Sign up to receive
    the latest NanoTemper news, product updates, event announcements and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Read
  • 6  protein degradation conferences in 2021 you can’t afford to miss

    6 protein degradation conferences in 2021 you can’t afford to miss

    Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...

    Read
  • Understanding the nuances of targeted protein degradation59:35

    Understanding the nuances of targeted protein degradation

    Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte

    Watch
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

    Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

    Read
  • PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...

    Read
  • Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

    Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

    Read
  • Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA

    Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA

    Read
  • The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

    The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

    Read
  • A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

    A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

    Read
  • loading
    Loading more...